| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ZBIO | Common Stock | Conversion of derivative security | +41.1K | +14.29% | 329K | Sep 16, 2024 | By Fairmount Healthcare Fund II LP | F1, F2, F3 | ||
| transaction | ZBIO | Common Stock | Conversion of derivative security | +253K | +76.86% | 582K | Sep 16, 2024 | By Fairmount Healthcare Fund II LP | F2, F3, F4 | ||
| transaction | ZBIO | Common Stock | Conversion of derivative security | +710K | +121.97% | 1.29M | Sep 16, 2024 | By Fairmount Healthcare Fund II LP | F2, F3, F5 | ||
| transaction | ZBIO | Common Stock | Conversion of derivative security | +301K | +23.31% | 1.59M | Sep 16, 2024 | By Fairmount Healthcare Fund II LP | F2, F3, F6 | ||
| transaction | ZBIO | Common Stock | Purchase | $5.1M | +300K | +18.83% | $17.00 | 1.89M | Sep 16, 2024 | By Fairmount Healthcare Fund II LP | F2, F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ZBIO | Series Seed Convertible Preferred Stock | Conversion of derivative security | -357K | -100% | 0 | Sep 16, 2024 | Common Stock | 41.1K | By Fairmount Healthcare Fund II LP | F1, F3 | |||
| transaction | ZBIO | Series A Convertible Preferred Stock | Conversion of derivative security | -2.2M | -100% | 0 | Sep 16, 2024 | Common Stock | 253K | By Fairmount Healthcare Fund II LP | F3, F4 | |||
| transaction | ZBIO | Series B Convertible Preferred Stock | Conversion of derivative security | -6.16M | -100% | 0 | Sep 16, 2024 | Common Stock | 710K | By Fairmount Healthcare Fund II LP | F3, F4, F5 | |||
| transaction | ZBIO | Series C Convertible Preferred Stock | Conversion of derivative security | -2.61M | -100% | 0 | Sep 16, 2024 | Common Stock | 301K | By Fairmount Healthcare Fund II LP | F3, F5, F6 | |||
| transaction | ZBIO | Stock Option (Right to Buy) | Award | $0 | +37K | $0.00 | 37K | Sep 12, 2024 | Common Stock | 37K | $17.00 | By Tomas Kiselak | F7, F8 |
| Id | Content |
|---|---|
| F1 | On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. |
| F2 | The original Form 4, filed on September 16, 2024 is being amended by this Form 4 solely to correct the previously reported "Amount of Securities Beneficially Owned Following Reported Transactions." This amended Form 4 does not report any new transactions or otherwise modify the transaction details that were previously reported. |
| F3 | Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. ("Fund II"). The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| F4 | On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. |
| F5 | On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. |
| F6 | On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. |
| F7 | The option vests in equal annual installments over three years beginning on September 12, 2025, the first anniversary of the vesting commencement date, subject to continued service. |
| F8 | Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein. |
Fairmount may be deemed a director by deputization of the Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of the Issuer and is a Managing Member of Fairmount.